NRx Pharmaceuticals, Inc. (NRXP)

NASDAQ: NRXP · Real-Time Price · USD
2.520
-0.060 (-2.33%)
At close: Aug 28, 2025, 4:00 PM
2.502
-0.018 (-0.72%)
After-hours: Aug 28, 2025, 4:03 PM EDT
-2.33%
Market Cap60.29M
Revenue (ttm)n/a
Net Income (ttm)-33.79M
Shares Out 23.77M
EPS (ttm)-2.35
PE Ration/a
Forward PE16.06
Dividendn/a
Ex-Dividend Daten/a
Volume282,697
Open2.560
Previous Close2.580
Day's Range2.500 - 2.600
52-Week Range1.100 - 6.010
Beta1.60
AnalystsStrong Buy
Price Target29.25 (+1,053.21%)
Earnings DateAug 18, 2025

About NRXP

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusi... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 2
Stock Exchange NASDAQ
Ticker Symbol NRXP
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for NRXP stock is "Strong Buy." The 12-month stock price target is $29.25, which is an increase of 1,053.21% from the latest price.

Price Target
$29.25
(1,053.21% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine)

WILMINGTON, Del., Aug. 27, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, today announced its expanded access policy for NRX-100 (preserv...

1 day ago - GlobeNewsWire

NRx Pharmaceuticals, Inc. (NRXP) Q2 2025 Earnings Call Transcript

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q2 2025 Earnings Conference Call August 20, 2025 8:00 AM ET Company Participants Jonathan C. Javitt - Co-Founder, Chief Scientist Officer, Chairman & Interim C...

8 days ago - Seeking Alpha

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

NRx Drug Development Grant of expanded Fast Track Designation for NRX-100 from the FDA for all indications and types of depression and related disorders based on its potential to satisfy an unmet medi...

10 days ago - GlobeNewsWire

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025

Conference Call 8:00am ET, Wednesday August 20, 2025 WILMINGTON, Del. , Aug. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage ...

14 days ago - PRNewsWire

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025

WILMINGTON, Del., Aug. 11, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it...

17 days ago - GlobeNewsWire

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression

This designation expands the addressable population for NRX-100 to the 13 million Americans who consider suicide each year and represents a 10x expansion of the addressable population compared to the ...

17 days ago - PRNewsWire

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Receipt of Final Clearance to Proceed to Closing of Dura Medical Acquisition from Florida's Agency for Health Care Administration (AHCA)

Florida's Agency for Health Care Administration (AHCA) approval is a critical regulatory step toward closing the Dura Medical acquisition Dura Medical, together with previously-announced acquisitions ...

20 days ago - PRNewsWire

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of a Citizen Petition with the US Food and Drug Administration Seeking Removal of Benzethonium Chloride from Ketamine Products

Sterile ketamine products currently for sale in the United States contain benzethonium chloride, a preservative with known toxicity that is not Generally Recognized as Safe and Effective by the US Foo...

24 days ago - PRNewsWire

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Join Fireside Chat at BTIG Virtual Biotech Conference July 29 - 30, 2025

WILMINGTON, Del. , July 29, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), today announced that its CEO and Chairman will join a fireside chat...

4 weeks ago - PRNewsWire

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional Psychiatry Clinics

Cohen and Associates is a highly respected neuropsychiatry clinic in western Florida Cohen to serve as foundational clinic in the Sarasota - Bradenton area of Florida Acquisition expected to be immedi...

2 months ago - PRNewsWire

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100)

Company has applied for new Commissioner's National Priority Vouchers (CNPV) for NRX-100. Continues to anticipate decisions on drug approval by year-end 2025 Application under CNPV program is accretiv...

2 months ago - PRNewsWire

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners

WILMINGTON, Del. , June 16, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeu...

2 months ago - PRNewsWire

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

WILMINGTON, Del. , June 12, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeu...

2 months ago - PRNewsWire

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine

Ketamine faces a current US drug shortage not expected to abate in the near future1 Current ketamine market estimated at $750 million and projected to reach $3.35 billion globally in 2034.2  NRx antic...

3 months ago - PRNewsWire

NRx Pharmaceuticals, Inc. (NRXP) Q1 2025 Earnings Call Transcript

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Matthew Duffy – Chief Business Officer Jonathan Javitt – Founder, Chairman, and C...

3 months ago - Seeking Alpha

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update

Company has continued to advance its previously announced plan to obtain FDA approval for two new drugs and to develop a network of clinics focused on neuroplastic therapies to treat severe and suicid...

3 months ago - PRNewsWire

HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions

Term sheet with Universal Capital, LLC to fund HOPE Therapeutics clinic acquisition strategy Funding tied to already-announced acquisitions, with additional tranches contemplated for further growth, s...

3 months ago - PRNewsWire

HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics

Kadima Neuropsychiatry Institute in La Jolla, CA expected to serve as clinical model for Hope treatment offerings nationwide Kadima is a leading investigative site for CNS and psychedelic research, ha...

3 months ago - PRNewsWire

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025

WILMINGTON, Del. , May 12, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it wil...

3 months ago - PRNewsWire

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Investor Event at Mar-A-Lago Club on May 8, 2025

MIAMI , May 6, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology-driven company and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ...

4 months ago - PRNewsWire

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Patent Application for NRX-100, its Proprietary, Preservative Free Formulation of IV Ketamine

Patent expected to be Orange Book listable, if granted NRX-100, preservative free, IV ketamine, is designed to avoid potential toxicity concerns linked to benzethonium chloride, used in currently avai...

4 months ago - PRNewsWire

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces FDA Award of Filing Fee Waiver for Upcoming NRX-100 (preservative free ketamine) New Drug Application to Treat Patients with Suicidal Depression

Waiver exempts NRx from paying a $4.3 million New Drug Application filing fee under the Prescription Drug User Fee Act (PDUFA) Company is on track for Q2 2025 completion of NDA filing and PDUFA date b...

4 months ago - PRNewsWire

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc.to Participate in an H.C. Wainwright @ Home Fireside Discussion on Tuesday, April 22, 2025

WILMINGTON, Del. , April 21, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics,...

4 months ago - PRNewsWire

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE

Investment to support initiation of HOPE's network of clinics to treat suicidal depression and PTSD with ketamine, TMS and other modalities MIAMI , April 3, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc...

5 months ago - PRNewsWire

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics

Dura Medical, together with previously-announced acquisition of Neurospa TMS, will provide coverage throughout the West Coast of Florida Delivers a full range of precision psychiatry services for seve...

5 months ago - PRNewsWire